Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article Demonstrating Advancement in the Company’s Technology to Treat Diabetes
Ness Ziona, Israel,
|
May 11, 2021 07:00 AM Eastern Daylight Time
Kadimastem (TASE: KDST), a clinical stage biotechnology company announced today that the peer-reviewed journal Frontiers in Endocrinology has published an article in a focused issue on advances in stem cell technology to model and treat diabetes (click here to access the full article). The article describes the results of collaborative research conducted by Kadimastem’s R&D team in concert with scientists from the Weizmann Institute of Science.
The article details the important milestones achieved thus far in the pre-clinical development of Kadimastem’s diabetes product, IsletRx, and their translation to clinical application. IsletRx is composed of clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. Using micro-encapsulation technology, integrated within IsletRx, the islet cells are protected from an attack response by the host immune system.
The article details the advantages of Kadimastem’s novel selection and purification process technology currently utilized in the production of IsletRx. By employing Functional Cell-Capture Screening (FCCS) technology, the scientists identified unique signature cell-surface markers that enable them to select and enrich the IsletRx product with a population of highly effective cells. The selection process also eliminates cells that may not be necessary for function, and even may impair the efficacy and/or the safety of the transplanted cells. These results position IsletRx as a potential cure for many insulin dependent diabetes patients.
Kadimastem has renewed its focus on the advances in its diabetes project and its strategic positioning among other leading cell therapy companies worldwide. The Company’s technology is singular in its ability to refine the composition of Islet cells differentiated from hPSC by negative selection to remove un-needed cells and positive selection for selecting highly functional insulin producing cells to achieve the maximum therapeutic effect.
“The implications of this proprietary technology developed by our team and the WIS scientists, could be tremendously important in developing effective therapies for hundreds of millions of people living with diabetes,” said Asaf Shiloni, Chief Executive Officer of Kadimastem. “We are immensely proud of the work of our scientific team, led by Kadimastem Chief Scientist and Israel Prize winner Professor Michel Revel. His vision guides the research presented in this important article and the work provides a solid foundation to continue advancing Kadimastem’s mission to develop and provide a cell therapy cure for diabetes.”
Dr. Kfir Molakandov, head of Kadimastem’s diabetes cell therapy program said, “The research results published in Frontiers in Endocrinology will enable an improved and safer cell therapy product development. We have managed to demonstrate that we have the capability to manufacture the islets in a good, reproducible way and our proof-of-concept studies show that treatment with IsletRx is capable of ameliorating glycaemia in diabetic animals for a prolonged period of time.”
Social Media: LinkedIn, Twitter, Facebook
Company Contacts:
Asaf Shiloni
CEO
Press Contact:
Marjie Hadad
General Manager
Must Have Communications
917-790-1178
marjie@mhc-pr.com
About Kadimastem:
Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).
Forward Looking Statement:
This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future.
Contact Details
Asaf Shiloni
+972 73-797-1613
